VaxInnate

About VaxInnate

VaxInnate Corporation was a privately-held biotechnology firm that operated in the pharmaceutical manufacturing industry, focusing on the development of novel vaccines for infectious diseases. Founded in 2002 by Yale University professors Ruslan Medzhitov and Richard Flavell, leaders in the field of innate immunity, the company established its headquarters in New Jersey in 2004 to leverage the region's talent pool.

The company's core technology centered on its proprietary Toll-like receptor (TLR) platform. This approach involved genetically fusing vaccine antigens to the bacterial protein flagellin, which acts as a potent stimulator of the innate immune system by binding to TLR5. This method was designed to trigger both the innate and adaptive immune systems, potentially improving vaccine potency, manufacturing scalability, and cost-effectiveness compared to traditional egg-based production. The production process utilized low-cost, highly scalable recombinant DNA techniques.

VaxInnate's pipeline primarily targeted seasonal and pandemic influenza, with its lead candidate being VAX2012Q, a quadrivalent seasonal flu vaccine. The company also pursued vaccine development for other infectious diseases such as dengue, Clostridium difficile, malaria, and human papillomavirus (HPV). Throughout its operation, VaxInnate progressed several candidates through Phase 1 and Phase 2 clinical trials, demonstrating promising immunogenicity, particularly in elderly populations.

The company's business model relied on securing significant funding from both venture capital and government contracts to finance its extensive research and development programs. It successfully raised capital through multiple financing rounds, including a $40M Series C in 2006 and a $30M Series D in 2009. A key financial milestone was a contract awarded in 2011 by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of its flu vaccines. The company also received non-dilutive financing through New Jersey's Technology Business Tax Certificate Transfer Program. In 2012, Emergent BioSolutions acquired the exclusive U.S. rights to manufacture and sell VaxInnate's pandemic influenza vaccine candidate. Despite these developments, public records indicate the company ceased operations around February 2017.